Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
Renal Drug Excretion: Tubular Secretion01:28

Renal Drug Excretion: Tubular Secretion

Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Repolarization and Activation Mapping in Ventricular Tachycardia Ablation: The REDEEM Study.

JACC. Clinical electrophysiology·2026
Same author

Incidence, Mechanistic Insights, and Ablation of Atrial Tachycardia Occurring After Pulsed Field Ablation for Atrial Fibrillation: Results From a Large International Registry.

JACC. Clinical electrophysiology·2026
Same author

Left Atrial Appendage Occlusion Versus Direct Oral Anticoagulation in Atrial Fibrillation Patients at Very High Risk of Stroke: A Budget Impact Analysis in Italy.

Journal of clinical medicine·2026
Same author

Machine learning prediction of outcome following pulsed-field atrial fibrillation ablation: patient selection and risk factors.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2026
Same author

Role of transcatheter ablation in ischaemic ventricular tachycardia: should we be using it more?

European heart journal supplements : journal of the European Society of Cardiology·2026
Same author

Pulsed field ablation for atrial fibrillation in patients with heart failure: insight from the ATHENA registrys.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2026
Same journal

[Rufus of Ephesus, On gout].

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia·2026
Same journal

A Case Report and Literature Review: Chlorhexidine-induced anaphylaxis in a hemodialysis patient.

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia·2026
Same journal

New Frontiers in the Treatment of Chronic Kidney Disease-associated Pruritus: A Case of Hemoperfusion with HA130.

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia·2026
Same journal

Fibronectin Glomerulopathy: A Case Report of Membranoproliferative Glomerulonephritis.

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia·2026
Same journal

Sodium Disorders in Multiple Myeloma: Beyond Pseudohyponatremia to Clinical Pitfalls and Mechanistic Insights.

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia·2026
Same journal

Acute Kidney Injury and Early Diagnostic Biomarkers: A Narrative Literature Review.

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia·2026
See all related articles

Related Experiment Video

Updated: May 22, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

[Statins and kidney disease].

Roberto Bigazzi1, Daniela Grimaldi, Stefano Bianchi

  • 1Dipartimento di Medicina Clinica e Specialistica, USL6, Livorno, Italy. r.bigazzi@usl6.toscana.it

Giornale Italiano Di Nefrologia : Organo Ufficiale Della Societa Italiana Di Nefrologia
|April 28, 2012
PubMed
Summary
This summary is machine-generated.

Statins, used to manage abnormal lipid levels, show promise in reducing cardiovascular disease and potentially slowing kidney disease progression in chronic kidney disease (CKD) patients. This review explores the evidence linking statin therapy to improved cardiovascular and renal outcomes in CKD.

Related Experiment Videos

Last Updated: May 22, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Area of Science:

  • Nephrology
  • Cardiology
  • Endocrinology

Context:

  • Chronic kidney disease (CKD) prevalence is rising globally, driven by obesity, metabolic syndrome, hypertension, and diabetes.
  • CKD significantly increases cardiovascular disease (CVD) risk, which is the primary cause of death in CKD patients.
  • CKD is associated with common lipid metabolism abnormalities, including elevated LDL, triglycerides, VLDL, and lipoprotein(a), and reduced HDL cholesterol, contributing to CVD and potentially renal disease progression.

Purpose:

  • To review the evidence on the role of statins in managing dyslipidemia in CKD patients.
  • To examine the impact of statins on cardiovascular outcomes in CKD.
  • To assess the effects of statins on the progression of renal disease in CKD patients.

Summary:

  • Statins, HMG-CoA reductase inhibitors, are widely used to reduce cardiovascular risk in the general population.
  • Secondary analyses of CKD subgroups in statin trials suggest benefits for cardiovascular outcomes and, with more conflicting evidence, for renal disease progression.
  • Statins lower LDL cholesterol and possess pleiotropic effects impacting vascular tissue, kidneys, bone, and glucose metabolism, relevant to CKD management.

Impact:

  • Dyslipidemia management with statins may improve cardiovascular health in CKD patients.
  • Statins might play a role in mitigating the decline of renal function in individuals with CKD.
  • Understanding statins' multifaceted effects is crucial for optimizing treatment strategies in CKD patients with associated lipid abnormalities.